期刊文献+

阿魏酸哌嗪联合厄贝沙坦治疗糖尿病肾病的临床疗效及安全性评价 被引量:23

Clinical efficacy and safety of piperazine ferulate combined with irbesartan in the treatment of diabetic nephropathy
原文传递
导出
摘要 目的评价阿魏酸哌嗪联合厄贝沙坦治疗糖尿病肾病的临床疗效及安全性。方法将74例糖尿病肾病患者随机分为试验组37例和对照组37例。对照组予以口服厄贝沙坦150 mg,每天一次;试验组在对照组基础上,加用口服阿魏酸哌嗪150 mg,每天一次。2组患者疗程均为12周。观察2组患者的临床疗效、血清肌酸酐、血糖、血尿素氮、尿白蛋白排泄率、血流动力学指标,以及不良反应发生情况。结果治疗后,试验组的总有效率94.59%显著高于对照组75.68%(P<0.05)。治疗后,试验组的血清肌酸酐、尿白蛋白排泄率、血流动力学指标改善程度显著优于对照组(P<0.05)。2组患者治疗前后的血糖、血尿素氮水平比较差异无统计学意义(P>0.05)。2组患者均出现不同程度的恶心、呕吐、腹痛、头晕等不良症状,经对症处理后好转,但组间比较差异无统计学意义(P>0.05)。结论阿魏酸哌嗪联合厄贝沙坦治疗糖尿病肾病的临床疗效确切,能改善肾血流动力学,保护肾功能,降低尿蛋白水平。 Objective To evaluate the clinical efficacy and safety of piperazine ferulate combined with irbesartan in the treatment of diabetic nephropathy. Methods A total of 74 patients with diabetic nephropathy were randomly divided into treatment group( n = 37) and control group( n = 37). Control group was received irbesartan 150 mg,once a day.Treatment group was given piperazine ferulate 150 mg,once a day on the basis of control group. The treatment course of two groups was 12 weeks.The clinical efficacy, serum creatinine, blood glucose, blood urea nitrogen,urinary albumin excretion rate,hemodynamic level and adverse drug reactions were compared between two groups. Results After treatment,total effective rate in treatment group was significantly higher than that in control group( 94. 59% vs 75. 68%,P〈0. 05). After treatment,serum creatinine,urinary albumin excretion rate,hemodynamic level in treatment group were significantly better than those of control group( P〈0. 05). The blood glucose and blood urea nitrogen in two group were no obvious change( P〈0. 05). Patients in two groups showed different degrees of nausea,vomiting,abdominal pain,dizziness and other symptoms,but after symptomatic treatment turn,they were got better.There were no statistical significance of the incidence of adverse drugreactions between two groups( P〉0. 05). Conclusion Piperazine ferulate combined with irbesartan in the treatment of diabetic nephropathy patients was effective,which can improve the renal hemodynamics,protect the renal function,and reduce the proteinuria.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2016年第4期294-296,共3页 The Chinese Journal of Clinical Pharmacology
基金 2014年山东省自然科学基金资助项目(2014ZRE27036)
关键词 阿魏酸哌嗪 厄贝沙坦 糖尿病肾病 肾功能 临床疗效 安全性 piperazine ferulate irbesartan diabetic nephropathy renal function clinical efficacy safety
  • 相关文献

参考文献3

二级参考文献13

  • 1Rocco MV, Berns JS. KDOQI Clinical Practice Guideline for Diabetes and CKD : 2012 Update [ J ]. American Journal of Kidney Diseases, 2012, 60 (5): 850-886. 被引量:1
  • 2Jardine MJ, Hata J, Woodward M, et al. Prediction of kidney - relat- ed outeomes in patients with type 2 diabetes [J]. American Journal ot Kidney Diseases, 2012, 60 (5): 770-778. 被引量:1
  • 3Gross JL, De Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment [J] Diabetes Care, 2005, 28 (1): 164 -176. 被引量:1
  • 4American Diabetes Association. Standards of medical care in diabetes - 2009 [J]. Diabetes Care, 2009, 32 (Suppl 1): S13-S61. 被引量:1
  • 5Hilden J, Glasziou P. Regret graphs, diagnostic uncertainty and Youden's Index[J]. Statistics in Medicine, 1996, 15 (10):969- 986. 被引量:1
  • 6Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin ana- logues for the management of diabetes mellitus: a meta - analysis [ J] Canadian Medical Association Journal, 2009, 180 (4) : 385 -397. 被引量:1
  • 7Bed T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropa- thy Trial [ J ]. Journal of the American Society of Nephrology, 2005, 16 (7): 2170-2179. 被引量:1
  • 8Shichiri M, Kishikawa H, Ohkubo Y, et al. Long - term results of the Kumamoto Study on optimal, diabetes control in type 2 diabetic patients [Jl. Diabetes Care, 2000, 23 (Suppl 2) : B21 -B29. 被引量:1
  • 9ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Inten- sive blood glucose control and vascular outcomes in patients with type 2 diabetes [J]. N Engl J Med, 2008, 358 (24): 2560-2572. 被引量:1
  • 10Jorsal A, Tarnow L, Frystyk J, et al. Serum adiponectin predicts all - cause mortality and end stage renal disease in patients with type I dia- betes and diabetic nephropathy [ J ]. Kidney International, 2008, 74 (5) : 649 -654. 被引量:1

共引文献1299

同被引文献179

引证文献23

二级引证文献179

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部